Recursion Pharmaceuticals EBITDA vs. Price To Book
| RXRX Stock | USD 5.70 0.05 0.87% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -299.6 M | Current Value -284.6 M | Quarterly Volatility 90.1 M |
For Recursion Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Recursion Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Recursion Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Recursion Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Recursion Pharmaceuticals over time as well as its relative position and ranking within its peers.
Recursion |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Recursion Pharmaceuticals. If investors know Recursion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Recursion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Revenue Per Share 0.265 | Quarterly Revenue Growth 1.476 | Return On Assets (0.36) | Return On Equity (0.78) |
The market value of Recursion Pharmaceuticals is measured differently than its book value, which is the value of Recursion that is recorded on the company's balance sheet. Investors also form their own opinion of Recursion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Recursion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Recursion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Recursion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Recursion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Recursion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Recursion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Recursion Pharmaceuticals Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Recursion Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Recursion Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Recursion Pharmaceuticals is rated below average in ebitda category among its peers. It is rated third in price to book category among its peers . Recursion Pharmaceuticals reported EBITDA of (299.57 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Recursion Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Recursion Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Recursion Pharmaceuticals |
| = | (299.57 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Recursion Pharmaceuticals |
| = | 4.22 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Recursion Price To Book Comparison
Recursion Pharmaceuticals is currently under evaluation in price to book category among its peers.
Recursion Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Recursion Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Recursion Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Recursion Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Recursion Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 18.2 M | 19.1 M | |
| Interest Income | 18.3 M | 19.2 M | |
| Operating Income | -350.1 M | -332.6 M | |
| Net Loss | -292.6 M | -277.9 M | |
| Income Before Tax | -332.1 M | -315.5 M | |
| Total Other Income Expense Net | 17.9 M | 18.8 M | |
| Net Loss | -215.5 M | -226.3 M | |
| Net Loss | -328.1 M | -311.7 M | |
| Income Tax Expense | -4.1 M | -3.9 M | |
| Non Operating Income Net Other | -3.3 M | -3.5 M | |
| Change To Netincome | 45.2 M | 47.4 M | |
| Net Loss | (1.58) | (1.66) | |
| Income Quality | 0.88 | 0.77 | |
| Net Income Per E B T | 0.99 | 1.09 |
Recursion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Recursion Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Recursion Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Recursion Pharmaceuticals' important profitability drivers and their relationship over time.
Use Recursion Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Recursion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Recursion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Recursion Pharmaceuticals Pair Trading
Recursion Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Recursion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Recursion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Recursion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Recursion Pharmaceuticals to buy it.
The correlation of Recursion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Recursion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Recursion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Recursion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Recursion Pharmaceuticals position
In addition to having Recursion Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Momentum Thematic Idea Now
Momentum
Large corporations operating in software, education, financial and car manufacturing industries. The Momentum theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Momentum Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.